Cite
MLA Citation
C. Jackisch et al.. “1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status.” European journal of cancer, vol. 51, n.d., pp. S313–S314. http://access.bl.uk/ark:/81055/vdc_100030628182.0x00004c